Regulatory approval

Published by the Health Service Executive. Approved

As monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

This is written in the approval document.

Reimbursement

CDS

Citation

Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
HSE (1)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib

Contributions

Date	Contributor	Description
2025-05-01	Health Service Executive	Indication approved for reimbursement.
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database